Cancer clinical trials — recruiting now

The most common cancer in women in the U.S. Clinical trials test new therapies for early-stage, locally advanced, and metastatic breast cancer.

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Trials focus on targeted therapies, immunotherapy, and combination regimens.

The most common cancer in men in the U.S. Trials test hormonal, radiation, surgical, and novel therapies across risk groups.

Cancer of the colon or rectum. Trials span screening, adjuvant therapy, and metastatic disease.

One of the most aggressive cancers. Clinical trials are often the most direct path to access promising new therapies.

Epithelial ovarian cancer and related gynecologic malignancies. Trials focus on PARP inhibitors, immunotherapy, and maintenance strategies.

Cancers of the blood and bone marrow. Clinical trial participation is historically higher for leukemia than most solid tumors.

Hodgkin and non-Hodgkin lymphoma subtypes. Trials explore CAR-T therapy, bispecific antibodies, and relapsed/refractory regimens.

Primary brain tumors including glioblastoma multiforme (GBM), lower-grade gliomas, and other CNS malignancies.

Cancers of the oral cavity, pharynx, larynx, and salivary glands. HPV-driven and smoking-driven subtypes behave differently; trials often stratify on HPV status.

Largely HPV-driven. Trials span prevention, early-stage (often curable with surgery + radiation), and advanced/metastatic disease.

Rare cancers of bone and soft tissue. Many subtypes with distinct biology. Specialized sarcoma centers often run trials unavailable elsewhere.

Plasma cell malignancy. Trials test CAR-T, bispecific antibodies, and combination regimens in newly diagnosed and relapsed/refractory settings.

The most serious form of skin cancer. Trials span adjuvant, neoadjuvant, and metastatic disease — with major advances in immunotherapy.

Gastric adenocarcinoma. Trials test perioperative chemo-immunotherapy, HER2-targeted agents, and novel therapies for advanced disease.

Renal cell carcinoma (RCC) and related kidney malignancies.

Urothelial carcinoma of the bladder. Non-muscle-invasive and muscle-invasive disease both have active trial programs.

Hepatocellular carcinoma (HCC) and related primary liver malignancies.

The most common gynecologic cancer in the U.S. Trials focus on hormonally driven subtypes, MSI-H/dMMR immunotherapy, and advanced disease.

Squamous cell carcinoma and adenocarcinoma of the esophagus. Trials explore combination chemoradiation, immunotherapy, and perioperative regimens.

Papillary, follicular, medullary, and anaplastic thyroid carcinomas. Most are highly curable; trials focus on advanced and recurrent disease.

Highly curable germ cell tumors. Trials focus on reducing toxicity of curative therapy and treating relapsed/refractory disease.